Major Adverse Events With Chimeric Antigen Receptor T-Cell Therapy: Presentation, Diagnosis, and Resuscitation
Veronika Bachanová(University of Minnesota), Florian Merkle(Wright State University), Svatava Merkle(Cincinnati Children's Hospital Medical Center), Marketa Dimitrov(University of Minnesota Medical Center), Alex Hoover(University of Minnesota Medical Center)
Cited by 6
Related Papers
Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse
|Blood|2018|250
JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma
|Science|2024|173
Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)–an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT)
|Bone Marrow Transplantation|2019|119